About Atara Biotherapeutics (NASDAQ:ATRA)
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ATRA
- CUSIP: N/A
- Web: www.atarabio.com
Capitalization:- Market Cap: $446.16 million
- Outstanding Shares: 30,559,000
Average Prices:- 50 Day Moving Avg: $15.53
- 200 Day Moving Avg: $15.23
- 52 Week Range: $11.80 - $23.00
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.35
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $7.39 per share
- Price / Book: 1.98
Profitability:- EBITDA: ($98,030,000.00)
- Return on Equity: -39.54%
- Return on Assets: -37.40%
Debt:- Current Ratio: 19.38%
- Quick Ratio: 19.38%
Misc:- Average Volume: 181,998 shs.
- Beta: 1.38
- Short Ratio: 19.04
Frequently Asked Questions for Atara Biotherapeutics (NASDAQ:ATRA)
What is Atara Biotherapeutics' stock symbol?
Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."
How were Atara Biotherapeutics' earnings last quarter?
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) released its quarterly earnings data on Monday, August, 7th. The company reported ($0.94) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.89) by $0.05. View Atara Biotherapeutics' Earnings History.
When will Atara Biotherapeutics make its next earnings announcement?
Where is Atara Biotherapeutics' stock going? Where will Atara Biotherapeutics' stock price be in 2017?
5 brokerages have issued 12-month target prices for Atara Biotherapeutics' stock. Their forecasts range from $10.00 to $47.00. On average, they expect Atara Biotherapeutics' share price to reach $26.75 in the next year. View Analyst Ratings for Atara Biotherapeutics.
What are analysts saying about Atara Biotherapeutics stock?
Here are some recent quotes from research analysts about Atara Biotherapeutics stock:
- 1. According to Zacks Investment Research, "Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. " (8/28/2017)
- 2. Canaccord Genuity analysts commented, "Jounce announced initiation of the Phase 2 portion of the ICONIC study of JTX-2011." (4/21/2017)
Who are some of Atara Biotherapeutics' key competitors?
Some companies that are related to Atara Biotherapeutics include Flexion Therapeutics (FLXN), Intra-Cellular Therapies (ITCI), Reata Pharmaceuticals (RETA), Revance Therapeutics (RVNC), Cytokinetics, Incorporated (CYTK), Alder BioPharmaceuticals (ALDR), La Jolla Pharmaceutical Company (LJPC), Keryx Biopharmaceuticals (KERX), ZIOPHARM Oncology (ZIOP), CytomX Therapeutics (CTMX), PTC Therapeutics (PTCT), Vanda Pharmaceuticals (VNDA), Coherus BioSciences (CHRS), Aclaris Therapeutics (ACRS), Audentes Therapeutics (BOLD), Dova Pharmaceuticals (DOVA), Aduro Biotech (ADRO) and Adaptimmune Therapeutics PLC (ADAP).
Who are Atara Biotherapeutics' key executives?
Atara Biotherapeutics' management team includes the folowing people:
- Isaac E. Ciechanover M.D., Chairman of the Board, President, Chief Executive Officer
- John F. McGrath Jr., Chief Financial Officer, Executive Vice President
- Joseph Newell, Executive Vice President, Chief Technical Operations Officer
- Christopher M. Haqq M.D. Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
- Heather D. Turner, Executive Vice President, General Counsel, Secretary and Head of Portfolio Strategy
- Mitchall G. Clark, Executive Vice President and Chief Regulatory and Quality Assurance Officer
- Gad Soffer, Executive Vice President and Chief Strategy Officer
- Kanya Rajangam M.D. Ph.D., Senior Vice President, Chief Medical Officer
- Carol G. Gallagher Pharm.D., Lead Independent Director
- Eric L. Dobmeier, Independent Director
How do I buy Atara Biotherapeutics stock?
Shares of Atara Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Atara Biotherapeutics' stock price today?
One share of Atara Biotherapeutics stock can currently be purchased for approximately $14.60.
MarketBeat Community Rating for Atara Biotherapeutics (NASDAQ ATRA)MarketBeat's community ratings are surveys of what our community members think about Atara Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Atara Biotherapeutics (NASDAQ:ATRA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 1 Hold Rating, 3 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.40) |
| Consensus Price Target: | $26.75 (83.22% upside) |
Consensus Price Target History for Atara Biotherapeutics (NASDAQ:ATRA)
Analysts' Ratings History for Atara Biotherapeutics (NASDAQ:ATRA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/6/2017 | Goldman Sachs Group Inc | Reiterated Rating | Neutral -> Neutral | $20.00 | N/A |  |
| 10/5/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $30.00 | N/A | |
| 9/11/2017 | Canaccord Genuity | Reiterated Rating | Buy | $47.00 | High | |
| 6/26/2017 | William Blair | Reiterated Rating | Outperform | | Medium | |
| 3/16/2017 | Citigroup Inc. | Set Price Target | Sell | $10.00 | High | |
| 7/9/2016 | JMP Securities | Reiterated Rating | Buy | | N/A | |
| 3/9/2016 | J P Morgan Chase & Co | Lower Price Target | Market Outperform | $40.00 -> $34.00 | N/A | |
(Data available from 10/21/2015 forward)
Earnings History for Atara Biotherapeutics (NASDAQ:ATRA)Earnings History by Quarter for Atara Biotherapeutics (NASDAQ ATRA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/2/2017 | | ($0.97) | | | | | N/A | |
| 8/7/2017 | Q2 2017 | ($0.89) | ($0.94) | | | View | N/A | |
| 3/9/2017 | 12/31/2016 | ($0.98) | ($0.63) | | | View | N/A | |
| 11/4/2016 | Q3 2016 | ($0.79) | ($0.88) | | | View | N/A | |
| 8/8/2016 | Q2 | ($0.61) | ($0.66) | | | View | N/A | |
| 5/5/2016 | Q1 | ($0.55) | ($0.58) | | | View | N/A | |
| 3/3/2016 | Q4 2015 | ($0.48) | ($0.75) | | | View | N/A | |
| 11/5/2015 | Q3 2015 | ($0.53) | ($0.43) | | | View | N/A | |
| 8/6/2015 | Q215 | ($0.42) | ($0.43) | | | View | N/A | |
| 2/26/2015 | Q4 2014 | ($0.35) | ($0.67) | | | View | N/A | |
| 11/12/2014 | Q314 | | ($4.20) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Atara Biotherapeutics (NASDAQ:ATRA)2017 EPS Consensus Estimate: ($3.86)
2018 EPS Consensus Estimate: ($3.93)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.78) | ($0.75) | ($0.77) |
| Q2 2017 | 2 | ($0.92) | ($0.91) | ($0.92) |
| Q3 2017 | 2 | ($1.10) | ($0.95) | ($1.03) |
| Q4 2017 | 2 | ($1.32) | ($0.98) | ($1.15) |
| Q1 2018 | 1 | ($1.00) | ($1.00) | ($1.00) |
| Q2 2018 | 1 | ($1.00) | ($1.00) | ($1.00) |
| Q3 2018 | 1 | ($1.02) | ($1.02) | ($1.02) |
| Q4 2018 | 1 | ($0.91) | ($0.91) | ($0.91) |
(Data provided by Zacks Investment Research)
Dividend History for Atara Biotherapeutics (NASDAQ:ATRA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Atara Biotherapeutics (NASDAQ:ATRA)Insider Ownership Percentage: 16.20%
Institutional Ownership Percentage: 82.95%
Insider Trades by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/16/2017 | Christopher Haqq | EVP | Sell | 6,000 | $14.35 | $86,100.00 | |
| 10/12/2017 | Isaac E Ciechanover | CEO | Sell | 4,400 | $15.02 | $66,088.00 | |
| 10/11/2017 | Isaac E Ciechanover | CEO | Sell | 2,200 | $15.25 | $33,550.00 | |
| 9/20/2017 | Isaac E Ciechanover | CEO | Sell | 4,400 | $15.54 | $68,376.00 | |
| 9/15/2017 | Christopher Haqq | EVP | Sell | 6,000 | $15.30 | $91,800.00 | |
| 9/7/2017 | Isaac E Ciechanover | CEO | Sell | 4,400 | $15.02 | $66,088.00 | |
| 8/23/2017 | Isaac E Ciechanover | CEO | Sell | 4,400 | $13.54 | $59,576.00 | |
| 8/16/2017 | Carol Giltner Gallagher | Director | Sell | 1,184 | $14.30 | $16,931.20 | |
| 8/16/2017 | John Mcgrath | CFO | Sell | 4,200 | $14.31 | $60,102.00 | |
| 8/16/2017 | Mitchall G. Clark | EVP | Sell | 3,021 | $14.33 | $43,290.93 | |
| 8/15/2017 | Christopher Haqq | EVP | Sell | 7,604 | $14.75 | $112,159.00 | |
| 8/11/2017 | Isaac E Ciechanover | CEO | Sell | 4,400 | $14.67 | $64,548.00 | |
| 7/25/2017 | Isaac E Ciechanover | CEO | Sell | 5,500 | $16.49 | $90,695.00 | |
| 7/24/2017 | Isaac E Ciechanover | CEO | Sell | 2,800 | $16.94 | $47,432.00 | |
| 7/17/2017 | Christopher Haqq | EVP | Sell | 6,000 | $14.92 | $89,520.00 | |
| 6/15/2017 | Christopher Haqq | EVP | Sell | 6,000 | $12.65 | $75,900.00 | |
| 6/9/2017 | Carol Giltner Gallagher | Director | Sell | 1,000 | $13.15 | $13,150.00 | |
| 5/31/2017 | Isaac E Ciechanover | CEO | Sell | 6,900 | $13.35 | $92,115.00 | |
| 5/30/2017 | Isaac E Ciechanover | CEO | Sell | 3,450 | $13.44 | $46,368.00 | |
| 5/18/2017 | Isaac E Ciechanover | CEO | Sell | 4,800 | $14.91 | $71,568.00 | |
| 5/16/2017 | Carol Giltner Gallagher | Director | Sell | 1,184 | $15.25 | $18,056.00 | |
| 5/16/2017 | Gad Soffer | EVP | Sell | 12,674 | $15.16 | $192,137.84 | |
| 5/16/2017 | John Mcgrath | CFO | Sell | 4,000 | $15.11 | $60,440.00 | |
| 4/26/2017 | Isaac E Ciechanover | CEO | Sell | 7,200 | $17.56 | $126,432.00 | |
| 4/25/2017 | Isaac E Ciechanover | CEO | Sell | 3,600 | $17.33 | $62,388.00 | |
| 4/17/2017 | Christopher Haqq | EVP | Sell | 6,000 | $17.28 | $103,680.00 | |
| 4/11/2017 | Isaac E Ciechanover | CEO | Sell | 7,200 | $17.03 | $122,616.00 | |
| 3/28/2017 | Isaac E Ciechanover | CEO | Sell | 16,000 | $20.06 | $320,960.00 | |
| 3/23/2017 | John Mcgrath | CFO | Sell | 14,000 | $20.65 | $289,100.00 | |
| 3/17/2017 | Isaac E Ciechanover | CEO | Sell | 30,800 | $19.38 | $596,904.00 | |
| 3/10/2017 | Gad Soffer | EVP | Sell | 2,500 | $20.00 | $50,000.00 | |
| 3/10/2017 | John Mcgrath | CFO | Sell | 24,000 | $20.00 | $480,000.00 | |
| 2/21/2017 | John Mcgrath | CFO | Sell | 9,000 | $15.14 | $136,260.00 | |
| 2/16/2017 | Carol Giltner Gallagher | Director | Sell | 1,183 | $16.10 | $19,046.30 | |
| 2/16/2017 | Isaac E Ciechanover | CEO | Sell | 4,800 | $15.56 | $74,688.00 | |
| 2/16/2017 | Mitchall G. Clark | EVP | Sell | 3,059 | $15.96 | $48,821.64 | |
| 2/15/2017 | Christopher Haqq | EVP | Sell | 7,604 | $15.49 | $117,785.96 | |
| 2/10/2017 | Gad Soffer | EVP | Sell | 6,274 | $15.47 | $97,058.78 | |
| 2/9/2017 | Christopher Haqq | EVP | Sell | 13,975 | $15.46 | $216,053.50 | |
| 2/3/2017 | Isaac E Ciechanover | CEO | Sell | 4,800 | $13.66 | $65,568.00 | |
| 1/18/2017 | Isaac E Ciechanover | CEO | Sell | 6,000 | $14.24 | $85,440.00 | |
| 1/17/2017 | Christopher Haqq | EVP | Sell | 6,000 | $14.27 | $85,620.00 | |
| 1/6/2017 | Isaac E Ciechanover | CEO | Sell | 8,400 | $16.89 | $141,876.00 | |
| 12/23/2016 | Isaac E Ciechanover | CEO | Sell | 4,800 | $15.22 | $73,056.00 | |
| 12/15/2016 | Christopher Haqq | Insider | Sell | 6,000 | $15.40 | $92,400.00 | |
| 12/7/2016 | Isaac E Ciechanover | CEO | Sell | 7,200 | $17.93 | $129,096.00 | |
| 11/23/2016 | Isaac E Ciechanover | CEO | Sell | 12,000 | $18.34 | $220,080.00 | |
| 11/22/2016 | Isaac E Ciechanover | CEO | Sell | 8,400 | $18.21 | $152,964.00 | |
| 11/16/2016 | Carol Giltner Gallagher | Director | Sell | 1,184 | $19.35 | $22,910.40 | |
| 11/16/2016 | Gad Soffer | COO | Sell | 16,718 | $20.00 | $334,360.00 | |
| 11/16/2016 | Mitchall G Clark | Insider | Sell | 2,995 | $19.53 | $58,492.35 | |
| 11/14/2016 | Gad Soffer | COO | Sell | 9,582 | $20.55 | $196,910.10 | |
| 11/11/2016 | John Mcgrath | CFO | Sell | 5,000 | $19.84 | $99,200.00 | |
| 10/27/2016 | Isaac E Ciechanover | CEO | Sell | 4,800 | $13.81 | $66,288.00 | |
| 10/14/2016 | Isaac E Ciechanover | CEO | Sell | 4,800 | $15.96 | $76,608.00 | |
| 10/12/2016 | John Mcgrath | CFO | Sell | 5,000 | $17.47 | $87,350.00 | |
| 9/28/2016 | Isaac E Ciechanover | CEO | Sell | 12,000 | $20.87 | $250,440.00 | |
| 9/16/2016 | Isaac E Ciechanover | CEO | Sell | 7,200 | $19.36 | $139,392.00 | |
| 8/23/2016 | Isaac E Ciechanover | CEO | Sell | 9,600 | $22.33 | $214,368.00 | |
| 8/16/2016 | Gad Soffer | COO | Sell | 5,356 | $22.41 | $120,027.96 | |
| 8/15/2016 | Christopher Haqq | Insider | Sell | 1,346 | $22.32 | $30,042.72 | |
| 7/21/2016 | Isaac E Ciechanover | CEO | Sell | 9,600 | $22.11 | $212,256.00 | |
| 7/8/2016 | Isaac E Ciechanover | CEO | Sell | 9,600 | $22.88 | $219,648.00 | |
| 6/24/2016 | Isaac E Ciechanover | CEO | Sell | 9,600 | $21.26 | $204,096.00 | |
| 6/8/2016 | Isaac E Ciechanover | CEO | Sell | 12,000 | $20.53 | $246,360.00 | |
| 6/7/2016 | Isaac E Ciechanover | CEO | Sell | 7,200 | $20.36 | $146,592.00 | |
| 5/26/2016 | Isaac E Ciechanover | CEO | Sell | 7,200 | $17.69 | $127,368.00 | |
| 5/18/2016 | Carol Giltner Gallagher | Director | Sell | 1,184 | $15.96 | $18,896.64 | |
| 5/17/2016 | Gad Soffer | COO | Sell | 5,427 | $15.91 | $86,343.57 | |
| 5/16/2016 | John Mcgrath | CFO | Sell | 5,395 | $15.77 | $85,079.15 | |
| 5/16/2016 | Mitchall G Clark | Insider | Sell | 4,153 | $15.15 | $62,917.95 | |
| 4/26/2016 | Isaac E Ciechanover | CEO | Sell | 1,300 | $20.12 | $26,156.00 | |
| 4/12/2016 | Isaac E Ciechanover | CEO | Sell | 13,210 | $20.40 | $269,484.00 | |
| 4/1/2016 | Isaac E Ciechanover | CEO | Sell | 1,190 | $20.03 | $23,835.70 | |
| 3/17/2016 | Eric Dobmeier | Director | Buy | 3,000 | $13.86 | $41,580.00 | |
| 2/17/2016 | Carol Giltner Gallagher | Director | Sell | 1,183 | $16.30 | $19,282.90 | |
| 2/17/2016 | Gad Soffer | COO | Sell | 5,711 | $16.77 | $95,773.47 | |
| 1/14/2016 | Isaac E Ciechanover | CEO | Sell | 2,400 | $20.20 | $48,480.00 | |
| 12/31/2015 | Isaac E Ciechanover | CEO | Sell | 2,400 | $26.00 | $62,400.00 | |
| 12/16/2015 | Eric Dobmeier | Director | Buy | 2,500 | $22.00 | $55,000.00 | |
| 12/15/2015 | Isaac E Ciechanover | CEO | Sell | 2,400 | $22.46 | $53,904.00 | |
| 12/4/2015 | Isaac E Ciechanover | CEO | Sell | 4,000 | $37.45 | $149,800.00 | |
| 11/30/2015 | John Mcgrath | CFO | Sell | 6,000 | $40.00 | $240,000.00 | |
| 11/24/2015 | Isaac E Ciechanover | CEO | Sell | 4,800 | $35.03 | $168,144.00 | |
| 11/17/2015 | Carol Giltner Gallagher | Director | Sell | 1,184 | $31.10 | $36,822.40 | |
| 11/17/2015 | Gad Soffer | COO | Sell | 7,586 | $31.22 | $236,834.92 | |
| 10/22/2015 | Isaac E Ciechanover | CEO | Sell | 3,200 | $25.85 | $82,720.00 | |
| 10/7/2015 | Isaac E Ciechanover | CEO | Sell | 4,000 | $33.08 | $132,320.00 | |
| 9/24/2015 | Isaac E Ciechanover | CEO | Sell | 5,200 | $42.99 | $223,548.00 | |
| 9/11/2015 | Isaac E. Ciechanover | CEO | Sell | 5,200 | $46.16 | $240,032.00 | |
| 8/31/2015 | Christopher Haqq | insider | Sell | 5,000 | $41.99 | $209,950.00 | |
| 8/28/2015 | Isaac E Ciechanover | CEO | Sell | 5,200 | $39.25 | $204,100.00 | |
| 8/24/2015 | Carol Giltner Gallagher | Director | Sell | 17,622 | $42.34 | $746,115.48 | |
| 8/19/2015 | Carol Giltner Gallagher | Director | Sell | 5,875 | $48.18 | $283,057.50 | |
| 8/18/2015 | Carol Giltner Gallagher | Director | Sell | 5,764 | $49.38 | $284,626.32 | |
| 8/18/2015 | Gad Soffer | COO | Sell | 7,711 | $49.49 | $381,617.39 | |
| 8/18/2015 | John Mcgrath | CFO | Sell | 6,000 | $49.38 | $296,280.00 | |
| 8/17/2015 | Gad Soffer | COO | Sell | 8,778 | $50.00 | $438,900.00 | |
| 8/17/2015 | Mitchall G Clark | Insider | Sell | 7,829 | $46.19 | $361,621.51 | |
| 7/17/2015 | Isaac E Ciechanover | CEO | Sell | 5,200 | $60.71 | $315,692.00 | |
| 7/15/2015 | Christopher Haqq | Insider | Sell | 2,500 | $62.94 | $157,350.00 | |
| 7/1/2015 | Christopher Haqq | Insider | Sell | 2,500 | $51.68 | $129,200.00 | |
| 7/1/2015 | Isaac E Ciechanover | CEO | Sell | 5,200 | $50.42 | $262,184.00 | |
| 6/18/2015 | Isaac E Ciechanover | CEO | Sell | 5,200 | $54.72 | $284,544.00 | |
| 6/15/2015 | Christopher Haqq | Insider | Sell | 7,500 | $46.42 | $348,150.00 | |
| 6/15/2015 | John Mcgrath | CFO | Sell | 10,000 | $50.00 | $500,000.00 | |
| 6/5/2015 | Isaac E Ciechanover | CEO | Sell | 6,400 | $42.91 | $274,624.00 | |
| 6/1/2015 | Christopher Haqq | Insider | Sell | 2,500 | $41.47 | $103,675.00 | |
| 5/29/2015 | John Mcgrath | CFO | Sell | 10,000 | $40.00 | $400,000.00 | |
| 5/22/2015 | Isaac E Ciechanover | CEO | Sell | 4,000 | $37.56 | $150,240.00 | |
| 4/23/2015 | Isaac E Ciechanover | CEO | Sell | 5,200 | $61.36 | $319,072.00 | |
| 3/10/2015 | Joel S Marcus | Director | Buy | 4,000 | $29.57 | $118,280.00 | |
| 2/18/2015 | Carol Giltner Gallagher | Director | Buy | 11,000 | $18.00 | $198,000.00 | |
| 10/21/2014 | Domain Partners Viii, L.P. | Major Shareholder | Buy | 248,159 | $11.00 | $2,729,749.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Atara Biotherapeutics (NASDAQ:ATRA)
Latest Headlines for Atara Biotherapeutics (NASDAQ:ATRA)
| Source: |
|
Loading headlines, please wait.
Atara Biotherapeutics (ATRA) Chart for Saturday, October, 21, 2017
